Plain-English translation of NCT06933472 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called to see if it can help people on dialysis control high phosphate levels in their blood. High phosphate is a common problem for people with kidney disease on dialysis, and doctors are looking for better ways to manage it. The medication works by binding to phosphate so your body can remove it more easily.
People on dialysis often struggle to keep their phosphate levels in a healthy range, which can lead to bone problems and heart disease. This medication is being tested to see if it offers a new, effective option for managing this serious complication.
You likely qualify if…
You likely don't qualify if…
You will take the medication three times a day for about 8 weeks, and your doctor will adjust the dose based on your blood phosphate levels. After that, you'll continue taking the medication for an additional 24 weeks, and then take it for a final 3 weeks. Throughout the study, your blood will be tested regularly to check how well the medication is working and how you're tolerating it. The study lasts about 35 weeks in total.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States